

Randomized, placebo-controlled trial.

Cobitolimod is a Toll-like receptor-9 agonist DNA-based used topically. Patients with moderate-severe UC were randomized to 2 topical single doses 30 mg or placebo administered during colonoscopy at baseline and w4.

Primary outcome:

Clinical remission at w12.

Results:

- No statistical differences between therapy and placebo in clinical remission at w12, 44.4% vs 46.5%.

Conclusions:

Therapy with the topically applied TLR-9 agonist DIMS0150 is a promising and welltolerated novel therapeutic option for treatment-refractory, chronic active UC patients, warranting further clinical trials.

